Financial Enhancement Group LLC Has $2.50 Million Holdings in Danaher Co. (NYSE:DHR)

Financial Enhancement Group LLC decreased its position in shares of Danaher Co. (NYSE:DHR) by 6.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,408 shares of the conglomerate’s stock after selling 673 shares during the period. Financial Enhancement Group LLC’s holdings in Danaher were worth $2,497,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the company. Teachers Insurance & Annuity Association of America acquired a new stake in shares of Danaher in the third quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC acquired a new stake in Danaher in the 3rd quarter worth $50,000. Darwin Wealth Management LLC bought a new position in shares of Danaher during the 3rd quarter worth about $55,000. Finally, Modus Advisors LLC acquired a new position in shares of Danaher during the fourth quarter valued at about $56,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Up 0.1 %

Shares of DHR opened at $237.78 on Thursday. The stock’s fifty day simple moving average is $235.27 and its 200-day simple moving average is $253.56. The firm has a market capitalization of $171.74 billion, a PE ratio of 45.38, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. Danaher Co. has a 12-month low of $222.53 and a 12-month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company posted $2.02 EPS. The company’s revenue was up 3.1% compared to the same quarter last year. As a group, research analysts predict that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Ratings Changes

DHR has been the topic of a number of recent research reports. UBS Group decreased their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Bank of America raised Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Friday, December 13th. Evercore ISI upped their target price on Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. Stephens reiterated an “overweight” rating and set a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Barclays dropped their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $286.80.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.